CN103980194A - 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 - Google Patents
6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 Download PDFInfo
- Publication number
- CN103980194A CN103980194A CN201410204002.2A CN201410204002A CN103980194A CN 103980194 A CN103980194 A CN 103980194A CN 201410204002 A CN201410204002 A CN 201410204002A CN 103980194 A CN103980194 A CN 103980194A
- Authority
- CN
- China
- Prior art keywords
- ethyl
- quinoline
- formula
- compound
- suc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 COc1cc(C(*)O)cc2cccnc12 Chemical compound COc1cc(C(*)O)cc2cccnc12 0.000 description 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/32—Esters
- C07D215/34—Carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410204002.2A CN103980194B (zh) | 2014-05-15 | 2014-05-15 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
PCT/CN2015/078918 WO2015172722A1 (zh) | 2014-05-15 | 2015-05-14 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410204002.2A CN103980194B (zh) | 2014-05-15 | 2014-05-15 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103980194A true CN103980194A (zh) | 2014-08-13 |
CN103980194B CN103980194B (zh) | 2016-09-07 |
Family
ID=51272391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410204002.2A Active CN103980194B (zh) | 2014-05-15 | 2014-05-15 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103980194B (nl) |
WO (1) | WO2015172722A1 (nl) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015172722A1 (zh) * | 2014-05-15 | 2015-11-19 | 浙江省医学科学院 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
CN107417574A (zh) * | 2017-03-21 | 2017-12-01 | 浙江省医学科学院 | 2,4‑双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260784A (zh) * | 1997-06-17 | 2000-07-19 | 达尔文发现有限公司 | 作为pdeiv和tnf抑制剂的喹啉衍生物 |
CN1681791A (zh) * | 2002-07-16 | 2005-10-12 | 普拉纳生物技术有限公司 | 8-羟基喹啉衍生物 |
WO2011138751A2 (en) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
CN103298790A (zh) * | 2010-08-13 | 2013-09-11 | 维里奈奥公司 | 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006070394A1 (en) * | 2004-12-28 | 2006-07-06 | Council Of Scientific And Industrial Research | Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors |
WO2010086860A2 (en) * | 2009-01-29 | 2010-08-05 | Yeda Research And Development Co. Ltd. | Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them |
CN103980194B (zh) * | 2014-05-15 | 2016-09-07 | 浙江省医学科学院 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
-
2014
- 2014-05-15 CN CN201410204002.2A patent/CN103980194B/zh active Active
-
2015
- 2015-05-14 WO PCT/CN2015/078918 patent/WO2015172722A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1260784A (zh) * | 1997-06-17 | 2000-07-19 | 达尔文发现有限公司 | 作为pdeiv和tnf抑制剂的喹啉衍生物 |
CN1681791A (zh) * | 2002-07-16 | 2005-10-12 | 普拉纳生物技术有限公司 | 8-羟基喹啉衍生物 |
WO2011138751A2 (en) * | 2010-05-04 | 2011-11-10 | Pfizer Inc. | Heterocyclic derivatives as alk inhibitors |
CN103298790A (zh) * | 2010-08-13 | 2013-09-11 | 维里奈奥公司 | 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途 |
Non-Patent Citations (1)
Title |
---|
KARL S. A. VALLIN等: "Aqueous DMF-potassium carbonate as a substituted for thallium and silver additives in the palladium-catalyzed conversion of aryl bromides to acetyl arenes", 《THE JOURNAL OF ORGANIC CHEMISTRY》, vol. 66, no. 12, 22 May 2001 (2001-05-22), pages 4340 - 4343, XP001101812, DOI: doi:10.1021/jo015599f * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015172722A1 (zh) * | 2014-05-15 | 2015-11-19 | 浙江省医学科学院 | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 |
CN107417574A (zh) * | 2017-03-21 | 2017-12-01 | 浙江省医学科学院 | 2,4‑双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用 |
CN107417574B (zh) * | 2017-03-21 | 2019-12-03 | 浙江省医学科学院 | 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN103980194B (zh) | 2016-09-07 |
WO2015172722A1 (zh) | 2015-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Huang et al. | Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities | |
JP6373280B2 (ja) | イミダゾピリジン化合物及びその使用 | |
CN101321730B (zh) | 作为组胺h3受体调节剂的环丙胺 | |
US9814706B2 (en) | Hydrobromide salt of pridopidine | |
Zajdel et al. | Quinoline-and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor—5-HT1A/5-HT2A/5-HT7 and D2/D3/D4—agents: The synthesis and pharmacological evaluation | |
TW438781B (en) | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | |
CA2663280A1 (en) | Diaryl piperidine compounds as calcium channel blockers | |
CN105481706B (zh) | 一类2‑羟基查尔酮类化合物、其制备方法和用途 | |
Hei et al. | Synthesis and evaluation of 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors | |
BR112016030968B1 (pt) | Análogos de pridopidina, preparação e uso destes | |
CN105646417B (zh) | 一类4‑羟基噢哢类化合物、其制备方法和用途 | |
CN109280030B (zh) | 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用 | |
JP6704422B2 (ja) | キナゾリン誘導体の塩およびその製造方法 | |
CN106632181B (zh) | 噢哢曼尼希碱类化合物、其制备方法和用途 | |
KR20090018883A (ko) | 암치료용 히스톤 탈아세틸화 효소 저해제로서 엔-히드록시-3-(4-[3-페닐-에스-옥소-프로페닐]-페닐)-아크릴아미드 유도체 및 그 관련 화합물 | |
CN101948458A (zh) | 具有抗肿瘤活性的黄芩素衍生物及在医药上的应用 | |
CN103980194A (zh) | 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 | |
CN106831799A (zh) | 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途 | |
Darras et al. | Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl-or butyrylcholinesterase | |
CN104292280A (zh) | 一种氨糖噻唑衍生物及其合成方法与用途 | |
ES2362591B1 (es) | Compuestos multifuncionales modificadores de la enfermedad de alzheimer para el tratamiento de esta enfermedad. | |
Su et al. | Synthesis, characterization, crystal structure and biological evaluation of 1, 3, 5-triazine-quinoline derivatives as butyrylcholinesterase inhibitors | |
JP2023553094A (ja) | 中枢神経系障害の治療のためのセロトニン作動性薬としての3位環-アミンインドール誘導体 | |
US20110207745A1 (en) | Solid forms of 4--n,n-diethylbenzamide, compositions thereof, and uses therewith | |
CN109665969A (zh) | 3-甲氧基-4-羟基查尔酮双曼尼希碱类化合物、其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |